Abstracts
3427242
(#46) Healthcare Provider Perspectives on Real-World Use of TV-46000, a Long-Acting Subcutaneous Formulation of Risperidone, for Bipolar I Disorder
Abstract: Background: Long-acting injectable antipsychotics (LAIs) can address adherence challenges with oral antipsychotics in bipolar I disorder (BD-I) and improve clinical outcomes. TV-46000 once monthly is an LAI risperidone formulation approved for BD-I. This study investigated healthcare professional (HCP) perspectives on clinical value, treatment preferences, and clinical decision-making associated with prescribing TV-46000 for BD-I.
Methods: This cross-sectional survey included HCPs from practices managing BD-I for ≥2 years who had prescribed TV-46000 to adults with BD-I (without comorbid schizophrenia/schizoaffective disorder) between January 1, 2024-June 30, 2025. A structured, web-based questionnaire assessed perceived clinical value (relapse reduction, treatment adherence, patient convenience, and monitoring outcomes), treatment preference and satisfaction versus other antipsychotics, and factors influencing clinical decision-making related to TV-46000. Responses were summarized descriptively.
Results: Thirty-six HCPs completed the survey; 72% had >10 years of experience treating patients living with BD-I. Most agreed/strongly agreed that TV-46000 may reduce relapse rates/improve outcomes (97%), can improve adherence (94%), will allow better monitoring (86%), has manageable initiation/administration logistics (86%), and is acceptable/convenient to most patients (78%). 94% were overall satisfied/very satisfied with TV-46000 versus other antipsychotics, and 69% prefer/strongly prefer TV-46000 over other antipsychotics for BD-I for most patients. Key drivers of TV-46000 initiation versus oral antipsychotics were improved adherence (72%) and likelihood of reducing relapse rates/improving outcomes (72%). Reported patient-perceived barriers included injection fear/anxiety, cost/reimbursement considerations, and prior negative LAI experiences.
Conclusions: HCPs reported high perceived clinical value, satisfaction, and preference for TV-46000 in the management of BD-I, supporting its clinical utility in real-world practice.
Short Description: This cross-sectional survey evaluated healthcare professional perspectives on TV-46000 once monthly, a long-acting injectable risperidone for bipolar I disorder. The 36 respondents reported high perceived clinical value and satisfaction with TV-46000, with potential benefits in adherence, relapse reduction, and clinical monitoring in routine practice. These findings support the potential clinical utility of TV-46000 for treating BD-I in real-world clinical practice.
Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC
Methods: This cross-sectional survey included HCPs from practices managing BD-I for ≥2 years who had prescribed TV-46000 to adults with BD-I (without comorbid schizophrenia/schizoaffective disorder) between January 1, 2024-June 30, 2025. A structured, web-based questionnaire assessed perceived clinical value (relapse reduction, treatment adherence, patient convenience, and monitoring outcomes), treatment preference and satisfaction versus other antipsychotics, and factors influencing clinical decision-making related to TV-46000. Responses were summarized descriptively.
Results: Thirty-six HCPs completed the survey; 72% had >10 years of experience treating patients living with BD-I. Most agreed/strongly agreed that TV-46000 may reduce relapse rates/improve outcomes (97%), can improve adherence (94%), will allow better monitoring (86%), has manageable initiation/administration logistics (86%), and is acceptable/convenient to most patients (78%). 94% were overall satisfied/very satisfied with TV-46000 versus other antipsychotics, and 69% prefer/strongly prefer TV-46000 over other antipsychotics for BD-I for most patients. Key drivers of TV-46000 initiation versus oral antipsychotics were improved adherence (72%) and likelihood of reducing relapse rates/improving outcomes (72%). Reported patient-perceived barriers included injection fear/anxiety, cost/reimbursement considerations, and prior negative LAI experiences.
Conclusions: HCPs reported high perceived clinical value, satisfaction, and preference for TV-46000 in the management of BD-I, supporting its clinical utility in real-world practice.
Short Description: This cross-sectional survey evaluated healthcare professional perspectives on TV-46000 once monthly, a long-acting injectable risperidone for bipolar I disorder. The 36 respondents reported high perceived clinical value and satisfaction with TV-46000, with potential benefits in adherence, relapse reduction, and clinical monitoring in routine practice. These findings support the potential clinical utility of TV-46000 for treating BD-I in real-world clinical practice.
Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC
